Acute Optic Neuritis
Acute Optic Neuritis (AON) often presents as a partial or complete loss of vision in one or both eyes. In about 90 percent of presentations the visual disturbance is accompanied by eye pain. The National Multiple Sclerosis Society (NMSS) estimates, approximately 40-50 percent of patients experiencing a single episode of AON will progress to multiple sclerosis (MS) within 5-10 years. Currently, no treatment options exist for AON other than steroid administration.
Teva Neuroscience is conducting the OCTAGON study, a multi-centered, randomized double blind, placebo-controlled study to examine the effect of COPAXONE® (glatiramer acetate), a product currently approved for relapsing remitting multiple sclerosis (RRMS), versus placebo on AON symptoms and the loss of the retinal nerve fiber layer (RNFL) that usually occurs post an AON event.
Participants enrolled in the OCTAGON study must meet the following criteria:
- Be between the ages of 18 and 45
- Recently diagnosed with a first event of AON defined by the presentation of visual disturbances
- Enrolled in the trial no more than 9 days from the onset of symptoms
- Once they have completed the clinical trial, your patient may resume treatment with their physician
Patients must be enrolled within nine days of their first AON event, so eligible patients should visit http://www.tevaclinicaltrials.com/Acute-Optic-Neuritis/.
for more information and the location of the nearest research center.